BioCentury
ARTICLE | Company News

Breakthrough designation for GSK's tafenoquine

December 24, 2013 12:12 AM UTC

The not-for-profit Medicines for Malaria Venture (MMV) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted breakthrough therapy designation for tafenoquine ( SB 252263) to treat and p...